Penumbra (PEN) has wrapped up FY 2025 with fourth quarter revenue of US$385.4 million and basic EPS of US$1.21, set against very large reported earnings growth over the past year and a trailing net margin of 12.7%. The company has seen quarterly revenue move from US$315.5 million in Q4 2024 to US$385.4 million in Q4 2025, while basic EPS stepped from US$0.88 to US$1.21 over the same period. On a trailing 12 month basis, revenue reached about US$1.4 billion with basic EPS of US$4.57. With earnings growth far outpacing revenue and margins now firmly in double digits, the spotlight is on how durable this profitability profile looks as investors digest the latest numbers.
See our full analysis for Penumbra.With the headline figures on the table, the next step is to see how this earnings run rate and margin profile line up against the main narratives around Penumbra’s growth potential and execution over the past year.
See what the community is saying about Penumbra
TTM profit of US$177.7m on US$1.4b revenue
- Over the last twelve months, Penumbra generated about US$1.4b in revenue and US$177.7m in net income, which lines up with the 12.7% trailing net margin investors have been watching.
- Bulls argue that clinical data and new product launches can keep that earnings base growing, and the current numbers give them some support:
- Reported earnings over the last year grew by a very large multiple versus the prior year, while analysts are still only looking for around 17.2% yearly earnings growth from here, so bulls see a gap between what the business is currently producing and what is baked into forecasts.
- Revenue is forecast to grow about 11.5% per year, a touch above the 10.4% figure cited for the broader US market, which lines up with the bullish view that Penumbra’s procedures and devices are addressing large, underpenetrated therapy areas.
Strong recent profitability and above market growth forecasts are exactly what bullish investors point to when they argue the story is still playing out and want to walk through the full upside case in detail. 🐂 Penumbra Bull Case
EPS run rate near US$4.57 versus rich 75.5x P/E
- On a trailing basis, basic EPS sits at US$4.57, and against the current share price of US$341.94 that equates to a P/E of 75.5x, well above the 30.4x US Medical Equipment industry average and the 38.7x peer average cited in the analysis.
- Bears focus on that valuation gap and argue that even with growth, the current pricing leaves limited room for disappointment:
- With analysts using an aggregate price target of about US$360.13, the upside from US$341.94 is modest compared to the very high multiple investors are already paying, which is why skeptics question how much more optimism can reasonably be added to the story.
- The same data set shows the stock trading above a DCF fair value of roughly US$162.74, so critics see a wide gap between the cash flow based estimate and the market price, and use that as a key plank in the cautious narrative.
If you want to see how skeptics frame these numbers and where they think expectations are stretched, the detailed bearish narrative lays it out clearly. 🐻 Penumbra Bear Case
Quarterly EPS climbs from US$0.88 to just over US$1.20
- Looking at the recent quarters, basic EPS moved from US$0.88 in Q4 2024 to about US$1.21 in Q4 2025, while revenue went from US$315.5m to US$385.4m, so profitability per share has risen alongside a larger top line.
- The consensus narrative leans on this pattern to argue the business is scaling into its cost base, but it also flags areas to watch:
- Over the trailing twelve months, net income of US$177.7m compares with just US$14.0m in the earlier period in the data set, which supports the idea that margin structure has shifted, although the analysis still points to elevated spending on sales and R&D that could affect how much further margins move.
- Analysts expect margins to reach about 14.6% over the next few years from lower levels today, which is consistent with the recent trend in the numbers but also assumes continued execution in the core neurovascular and vascular franchises without major competitive or regulatory setbacks.
Next Steps
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Penumbra on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
With both upbeat and cautious narratives on the table, the real question is where you land. Take a close look at the details and move quickly to form your own view, starting with 2 key rewards.
See What Else Is Out There
For all the strong profit numbers, the sharp valuation premium, modest implied upside to the consensus target, and gap to the cited DCF value leave little room for error.
If that kind of pricing risk makes you hesitate, it is worth checking out 53 high quality undervalued stocks today so you can quickly focus on companies where expectations and current earnings look more closely aligned.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com